NCT03650491

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Fortis Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection

Detailed description

This study is designed to evaluate the safety, tolerability and antitumor activity of FOR46 in patients with relapsed or refractory multiple myeloma. This study will be conducted in two parts: Dose escalation: This part will evaluate increasing doses of FOR46 to identify the maximum tolerated dose (MTD). The first patient enrolled on the study will receive the lowest dose of FOR46. Once this dose is shown to be safe, a second patient will be enrolled at the next higher dose. Patients will continue to be enrolled into either single or multiple patient groups receiving increasing doses until the MTD is reached. Dose expansion: This part of the study will further evaluate the safety, tolerability and antitumor activity of FOR46 at a dose shown to be safe in the dose escalation part of the study.

Conditions

• Multiple Myeloma
• Multiple Myeloma in Relapse
• Multiple Myeloma With Failed Remission

Interventions

Type	Name	Description
DRUG	FOR46	FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46

Timeline

• Start date: 2019-04-03
• Primary completion: 2022-01-31
• Completion: 2022-01-31
• First posted: 2018-08-28
• Last updated: 2022-07-27

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study